The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
Dieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 406
Oncogenic FGFR3 gene fusions in bladder cancer
Williams, S. V., Hurst, C. D., & Knowles, M. A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds486 · Cited by 390
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
VI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0450 · Cited by 320
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0659 · Cited by 286
Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodríguez, C., & Theillet, C. G. (1997) · PubMed · Cited by 270
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas
Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1164 · Cited by 270
FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Kunii, K., Davis, L., Gorenstein, J., Hatch, H., Yashiro, M., Di Bacco, A., Elbi, C., & Lutterbach, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5229 · Cited by 269
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome
Yu, K., Herr, A. B., Waksman, G., & Ornitz, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14536 · Cited by 258
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.4 · Cited by 249
Marek, L., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 222
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
Parker, B. C., Annala, M. J., Cogdell, D. E., Granberg, K. J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67144 · Cited by 215
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 206
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
Heist, R. S., Mino-Kenudson, M., Sequist, L. V., Tammireddy, S., Morrissey, L., Christiani, D. C., Engelman, J. A., & Iafrate, A. J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aed28 · Cited by 204
Self-citationYadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Barrios, C. H., Liu, M.-C., Lee, S. C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0788-0 · Cited by 199
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
Zhao, G., Li, W.-Y., Chen, D., Henry, J. R., Li, H.-Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0306 · Cited by 189
FGFR2 gene amplification and clinicopathological features in gastric cancer
Matsumoto, K., Arao, T., Hamaguchi, T., Shimada, Y., Kato, K., Oda, I., Taniguchi, H., Koizumi, F., Yanagihara, K., Sasaki, H., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.603 · Cited by 188
Byron, S. A., Gartside, M., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 186
Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, J. D., & Knowles, M. A. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606016 · Cited by 180
Kim, H. R., Kim, D. J., Kang, D. R., Lee, J. G., Lim, S. M., Lee, C. Y., Rha, S. Y., Bae, M. K., Lee, Y. J., Kim, S. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8622 · Cited by 170
Sharpe, R., Pearson, A., Herrera-Abreu, M. T., Johnson, D., Mackay, A., Welti, J. C., Natrajan, R., Reynolds, A. R., Reis-Filho, J. S., Ashworth, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2727 · Cited by 167
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3950 · Cited by 167
Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Mühling, J., Hofele, C., Radlwimmer, B., Lichter, P., & Joos, S. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.01.005 · Cited by 165
A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes
Garcia, M. J., Pole, J. C. M., Chin, S.-F., Teschendorff, A., Naderi, A., Ozdag, H., Vias, M., Kranjac, T., Subkhankulova, T., Paish, C., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208741 · Cited by 164
Pardo, O. E., Latigo, J., Jeffery, R. E., Nye, E., Poulsom, R., Spencer-Dene, B., Lemoine, N. R., Stamp, G. W., Aboagye, E. O., & Seckl, M. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1576 · Cited by 160
Ware, K. E., Marshall, M. E., Heasley, L. R., Marek, L. A., Hinz, T. K., Hercule, P., Helfrich, B. A., Doebele, R. C., & Heasley, L. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014117 · Cited by 158
High‐resolution genomic and expression analyses of copy number alterations in breast tumors
Haverty, P. M., Fridlyand, J., Li, L., Getz, G., Beroukhim, R., Lohr, S., Wu, T. D., Cavet, G., Zhang, Z., & Chant, J. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20558 · Cited by 158
Zhang, J., Zhang, L., Su, X., Li, M., Xie, L., Malchers, F., Fan, S., Yin, X., Xu, Y., Liu, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2694 · Cited by 158
Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 157
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Bernard‐Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D. K., Ricol, D., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 157
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 156
Bai, A., Meetze, K. A., Vo, N. N. Y., Kollipara, S., Mazsa, E. K., Winston, W. M., Weiler, S., Poling, L. L., Chen, T., Ismail, N. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1489 · Cited by 151
Genomic and Expression Analysis of the 8p11–12 Amplicon in Human Breast Cancer Cell Lines
Ray, M. E., Yang, Z. Q., Albertson, D. G., Kleer, C. G., Washburn, J. G., Macoska, J. A., & Ethier, S. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1022 · Cited by 144
Dienstmann, R., Braña, I., Rodon, J. A., & Tabernero, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0163 · Cited by 144
Self-citationTargeting mutant fibroblast growth factor receptors in cancer
Greulich, H. E., & Pollock, P. M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.012 · Cited by 136
Takeda, M., Arao, T., Yokote, H., Komatsu, T., Yanagihara, K., Sasaki, H., Yamada, Y., Tamura, T., Fukuoka, K., Kimurâ, H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2743 · Cited by 136
Schildhaus, H., Heukamp, L. C., Merkelbach‐Bruse, S., Riesner, K., Schmitz, K., Binot, E., Paggen, E., Albus, K., Schulte, W., Ko, Y., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.102 · Cited by 134
The genomics and genetics of endometrial cancer
Bell, D. W., & Ohara (2012) · Advances in Genomics and Genetics · doi:10.2147/agg.s28953 · Cited by 129
Kim, K. B., Chesney, J. A., Robinson, D., Gardner, H., Shi, M. M., & Kirkwood, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1747 · Cited by 124
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0021 · Cited by 121
Harding, T. C., Long, L., Palencia, S., Zhang, H., Sadra, A., Hestir, K., Patil, N. S., Levin, A., Hsu, A. W., Charych, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005414 · Cited by 120
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 119
Harbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D. A., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buneß, A., Chatenay‐Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 114
Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
Zhang, K., Chu, K., Wu, X., Gao, H., Wang, J., Yuan, Y., Loera, S., Ho, K., Wang, Y., Chow, W. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2086 · Cited by 106
Bumbaca, D., Wong, A., Drake, E. A., Reyes, A. E., Lin, B. C., Stéphan, J.-P., Desnoyers, L., Shen, B., & Dennis, M. S. (2011) · mAbs · doi:10.4161/mabs.3.4.15786 · Cited by 105
The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer
van Rhijn, B. W. G., van der Kwast, T., Liu, L., Fleshner, N. E., Boström, P. J., Vis, A. N., Alkhateeb, S. S., Bangma, C. H., Jewett, M. A. S., Zwarthoff, E. C., et al. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.09.008 · Cited by 101
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88 · cited 1×
“Up to 80% of low-grade and low-stage tumors express mutant FGFR3, but this abnormality is found in less than 20% of invasive high-grade bladder cancer [52–57].”
BackgroundIssa, A., Gill, J. W., Heideman, M. R., Şahin, Ö., Wiemann, S., Dey, J. H., & Hynes, N. E. (2013) · Breast Cancer Research · doi:10.1186/bcr3379 · Cited by 79
Murphy, T., Darby, S., Mathers, M. E., & Gnanapragasam, V. J. (2009) · The Journal of Pathology · doi:10.1002/path.2657 · Cited by 78
Konecny, G. E., Kolarova, T. R., O’Brien, N. A., Winterhoff, B. J. N., Yang, G., Qi, J., Qi, Z., Venkatesan, N., Ayala, R., Luo, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0999 · Cited by 74
Zhao, W.-M., Wang, L., Park, H., Chhim, S., Tanphanich, M., Yashiro, M., & Kim, K. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0531 · Cited by 73
Gruel, N., Lucchesi, C., Raynal, V., Rodrigues, M., Pierron, G., Goudefroye, R., Cottu, P., Reyal, F., Sastre-Garau, X., Fourquet, A., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.013 · Cited by 70
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 68
Self-citationMiyake, M., Ishii, M., Koyama, N., Kawashima, K., Kodama, T., Anai, S., Fujimoto, K., Hirao, Y., & Sugano, K. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162768 · Cited by 67
FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells
Kim, S., Dubrovska, A., Salamone, R. J., Walker, J. R., Grandinetti, K. B., Bonamy, G. M. C., Orth, A. P., Elliott, J., Porta, D. G., García-Echeverría, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051671 · Cited by 61
Oliveras‐Ferraros, C., Cufí, S., Queralt, B., Vázquez‐Martín, A., Martín-Castillo, B., Llorens, R., Bosch‐Barrera, J., Brunet, J., & Menéndez, J. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.103 · Cited by 59
Gozgit, J. M., Squillace, R. M., Wongchenko, M. J., Miller, D., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Wang, F., Clackson, T., & Rivera, V. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2131-z · Cited by 59
Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy
Heinzle, C. F., Sutterlüty, H., Grusch, M., Grasl‐Kraupp, B., Berger, W., & Marian, B. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.566217 · Cited by 57
Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer
Semrad, T. J., & Mack, P. C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.001 · Cited by 48
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
Brunello, E., Brunelli, M., Bogina, G., Caliò, A., Manfrin, E., Nottegar, A., Vergine, M., Molino, A., Bria, E., Massari, F., et al. (2012) · Journal of experimental & clinical cancer research : CR · doi:10.1186/1756-9966-31-103 · Cited by 46
Biomarker-driven patient selection for early clinical trials
Dienstmann, R., Rodon, J. A., & Tabernero, J. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff3cb · Cited by 42
Self-citationMaruyama‐Takahashi, K., Shimada, N., Imada, T., Maekawa‐Tokuda, Y., Ishii, T., Ouchi, J., Kusaka, H., Miyaji, H., Akinaga, S., Tanaka, A., et al. (2008) · The Prostate · doi:10.1002/pros.20728 · Cited by 38
André, F., Bachelot, T., Campone, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.508 · Cited by 32
Dienstmann, R., André, F., Soria, J., Tabernero, J. M., de Braud, F., Cereda, R., Bahleda, R., Hollebecque, A., Delmonte, A., & Camboni, M. G. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32898-2 · Cited by 22
Self-citation
Cited by
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Self-citation
Metadata
- Authors
- Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 25
- Issue
- 3
- Pages
- 552-563
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2139046059
- Cited by
- 365
- References
- 96
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.